The CEO of a clinical phase 2 company needed to reposition the company’s existing business communication for development in a new indication.
MSC led a number of workshops to determine the new strategic direction of the company together with the company management. An extensive communication strategy was developed to communicate the new target product profile along with a new scientific MOA rationale. MSC established an investment presentation, tailoring it to fit in with the new strategy, upgraded the presentation’s graphical design and visual appearance, and crafted a credible storyline to use along with the investment presentation. Based on the main document, a series of confidential and non-confidential work packages as well as conference partnering folders were developed and delivered, which allowed the CEO and management to spend more time preparing for and initiating investor interactions.